Role of Lp(a) in ASCVD Risk

Key Takeaways

• Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
• Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
• Implementation is inconsistent due to barriers like lack of awareness and time constraints in clinical settings.
• Strategies to enhance uptake include routine integration, electronic health record reminders, and education for providers and families.